Stock ZLD ZELIRA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zelira Therapeutics Limited

Equities

ZLD

AU000000ZLD1

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 01:44:48 2024-04-26 am EDT 		5-day change 1st Jan Change
0.705 AUD -0.70% Intraday chart for Zelira Therapeutics Limited -0.70% -21.67%
Apr. 15 Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme MT
Feb. 22 Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 67.98 30.21 52.18 51.18 9.29 17.13
Enterprise Value (EV) 1 62.3 27.14 51.12 46.76 7.044 17.43
P/E ratio -39.1 x -8.47 x -6.51 x -5.84 x -0.65 x -2.73 x
Yield - - - - - -
Capitalization / Revenue 217 x 39.3 x 53.1 x 77.2 x 6.03 x 56.9 x
EV / Revenue 199 x 35.3 x 52.1 x 70.5 x 4.57 x 57.9 x
EV / EBITDA - - -7,830,004 x -5,186,925 x -553,243 x -2,585,386 x
EV / FCF -44.1 x -21 x -15.4 x -9.91 x -1.24 x -6.6 x
FCF Yield -2.27% -4.76% -6.49% -10.1% -80.8% -15.1%
Price to Book 10.9 x 9.72 x 1.51 x 1.35 x 0.26 x 0.54 x
Nbr of stocks (in thousands) 4,316 4,316 5,522 6,802 9,577 11,347
Reference price 2 15.75 7.000 9.450 7.525 0.9700 1.510
Announcement Date 8/31/18 8/30/19 8/28/20 8/30/21 8/31/22 9/29/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 0.3138 0.769 0.9818 0.6633 1.541 0.3011
EBITDA - - -6.528 -9.016 -12.73 -6.74
EBIT 1 -2.365 -3.317 -6.759 -9.38 -13.21 -7.164
Operating Margin -753.84% -431.26% -688.47% -1,414.1% -857.2% -2,379.17%
Earnings before Tax (EBT) 1 -1.73 -3.568 -7.015 -8.549 -12.41 -6.269
Net income 1 -1.73 -3.568 -7.015 -8.549 -11.95 -5.573
Net margin -551.32% -463.94% -714.53% -1,288.84% -775.35% -1,850.75%
EPS 2 -0.4025 -0.8269 -1.452 -1.289 -1.485 -0.5535
Free Cash Flow 1 -1.414 -1.291 -3.316 -4.719 -5.693 -2.64
FCF margin -450.53% -167.93% -337.78% -711.44% -369.51% -876.56%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/31/18 8/30/19 8/28/20 8/30/21 8/31/22 9/29/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - 0.29
Net Cash position 1 5.69 3.07 1.06 4.42 2.25 -
Leverage (Debt/EBITDA) - - - - - -0.0433 x
Free Cash Flow 1 -1.41 -1.29 -3.32 -4.72 -5.69 -2.64
ROE (net income / shareholders' equity) -24.5% -76.5% -37.3% -23.6% -33.8% -18.6%
ROA (Net income/ Total Assets) -20.7% -42.2% -21.5% -15.6% -21.4% -12.5%
Assets 1 8.356 8.459 32.63 54.8 55.77 44.55
Book Value Per Share 2 1.440 0.7200 6.260 5.560 3.680 2.800
Cash Flow per Share 2 1.320 0.7100 0.3100 0.7300 0.2900 0.0100
Capex - 0.03 0.02 - - -
Capex / Sales - 3.67% 1.63% - - -
Announcement Date 8/31/18 8/30/19 8/28/20 8/30/21 8/31/22 9/29/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ZELIRA THERAPEUTICS LIMITED Stock Zelira Therapeutics Limited
-21.67% 5.22M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ZLD Stock
  4. Financials Zelira Therapeutics Limited